The global cancer incidence continues to rise, making oncology one of the most critical threats to human health. JOINN's oncology pharmacology team has extensive preclinical experience in anti-tumor drug development. We have established a comprehensive oncology efficacy evaluation platform covering syngeneic tumor models, human tumor xenograft models, and evaluation systems for multiple hot targets to support pharmacodynamic studies of small molecules, antibodies, ADCs, CAR-T, oncolytic viruses, and nucleic acid therapeutics.
Syngeneic Tumor Models
| Tumor Type | Cell Line | Strain |
| Murine Lung Cancer | LLC | C57BL/6 |
| Murine Breast Cancer | 4T1 | BALB/c |
| Murine Melanoma | B16-F1 | C57BL/6 |
| Colorectal Cancer | MC38, CT26 | C57BL/6, BALB/c |
| Prostate Cancer | RM-1 | C57BL/6 |
Xenograft Tumor Models
| Tumor Type | Human Cell Lines | Immunodeficient Mouse Strains |
| Pancreatic Cancer | AsPC-1, Panc-1, BxPC-3 | BALB/c nude, NOD-SCID, NPG, NOG |
| Hepatocellular Carcinoma | Huh-7, SMMC-7721, HepG2, PLC | BALB/c nude, NPG, NOG, NCG |
| Lung Cancer | HCC827, A549, NCI-H1975 | BALB/c nude, NOD-SCID, NOG, NPG, NCG |
| Gastric Cancer | NUGC-4, NCI-N87, SGC-7901 | BALB/c nude, NOG, NPG, NCG |
| Esophageal Cancer | ECA109, KYSE150, KYSE410 | BALB/c nude, NOG |
| Colorectal Cancer | HCT116, HT29, HCT8 | BALB/c nude, NOG, NPG, NCG |
| Astrocytoma | U87MG, U251 | NOG, NPG |
| Hematological Malignancy | Daudi, Raji, RPMI-8226, Nalm6, HL-60, Jeko-1, Jurkat | BALB/c nude, NOG, NPG |
| Multiple Myeloma | MM.1S, RPMI 8826, NCI-H929 | BALB/c nude, NOG, NPG |
| Cervical Cancer | HeLa, Caski | BALB/c nude, NOG, NPG |
| Breast Cancer | MDA-MB-231, MDA-MB-468, MCF-7, BT474 | BALB/c nude, NPG |
| Ovarian Cancer | OVCAR-3, OVCAR-8, SK-OV-3 | BALB/c nude, NOG, NPG |
| Prostate Cancer | PC-3, LNCaP C4-2B | BALB/c nude, NOG, NPG |
